These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 35203711)

  • 1. Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment.
    Labandeira-Garcia JL; Labandeira CM; Valenzuela R; Pedrosa MA; Quijano A; Rodriguez-Perez AI
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19.
    Pedrosa MA; Valenzuela R; Garrido-Gil P; Labandeira CM; Navarro G; Franco R; Labandeira-Garcia JL; Rodriguez-Perez AI
    Clin Sci (Lond); 2021 Feb; 135(3):465-481. PubMed ID: 33479758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway.
    Felber R; New W; Riskin SI
    Cureus; 2024 Mar; 16(3):e55563. PubMed ID: 38576704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges.
    Sriram K; Loomba R; Insel PA
    Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29274-29282. PubMed ID: 33203679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of components of the renin-angiotensin system, rs2106809 polymorphism of the
    Zuraeva ZT; Vikulova OK; Malysheva NM; Nikankina LV; Zaytceva NV; Sukhareva OY; Shamhalova MS; Shestakova MV; Mokrysheva NG
    Probl Endokrinol (Mosk); 2023 Aug; 69(4):21-31. PubMed ID: 37694864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
    Alexandre J; Cracowski JL; Richard V; Bouhanick B;
    Therapie; 2020; 75(4):319-325. PubMed ID: 32553503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAAS Blockade and COVID-19: Mechanistic Modeling of Mas and AT1 Receptor Occupancy as Indicators of Pro-Inflammatory and Anti-Inflammatory Balance.
    Melissa Hallow K; Dave I
    Clin Pharmacol Ther; 2021 Apr; 109(4):1092-1103. PubMed ID: 33506503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-angiotensin system at the interface of COVID-19 infection.
    Gul R; Kim UH; Alfadda AA
    Eur J Pharmacol; 2021 Jan; 890():173656. PubMed ID: 33086029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice.
    Katsi V; Pavlidis G; Charalambous G; Tousoulis D; Toutouzas K
    Curr Hypertens Rev; 2022; 18(1):3-10. PubMed ID: 33475077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy with RAS inhibitors during the COVID-19 pandemic.
    Spaccarotella C; Mazzitelli M; Migliarino S; Curcio A; De Rosa S; Torti C; Indolfi C
    J Cardiovasc Med (Hagerstown); 2021 May; 22(5):329-334. PubMed ID: 33795584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.
    Kai H; Kai M
    Hypertens Res; 2020 Jul; 43(7):648-654. PubMed ID: 32341442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis.
    Sadria M; Layton AT
    PLoS Comput Biol; 2020 Oct; 16(10):e1008235. PubMed ID: 33031368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II receptors: Impact for COVID-19 severity.
    Aksoy H; Karadag AS; Wollina U
    Dermatol Ther; 2020 Nov; 33(6):e13989. PubMed ID: 32645228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin-angiotensin-aldosterone system and COVID-19 infection.
    Alexandre J; Cracowski JL; Richard V; Bouhanick B;
    Ann Endocrinol (Paris); 2020 Jun; 81(2-3):63-67. PubMed ID: 32370986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-angiotensin system inhibition in COVID-19 patients.
    de Vries AAF
    Neth Heart J; 2020 Jul; 28(7-8):396-405. PubMed ID: 32514935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review.
    Aleksova A; Gagno G; Sinagra G; Beltrami AP; Janjusevic M; Ippolito G; Zumla A; Fluca AL; Ferro F
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive medication uses and serum ACE2 levels: ACEIs/ARBs treatment does not raise serum levels of ACE2.
    Emilsson V; Gudmundsson EF; Aspelund T; Jonsson BG; Gudjonsson A; Launer LJ; Jennings LL; Gudmundsdottir V; Gudnason V
    medRxiv; 2020 May; ():. PubMed ID: 32511473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.
    Dworakowska D; Grossman AB
    J Physiol Pharmacol; 2020 Apr; 71(2):. PubMed ID: 32633235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Implications of Angiotensin-converting Enzyme 2 Blockades on Neuroinflammation in SARS-CoV-2 Infection.
    Paul D; Mohankumar SK; Thomas RS; Kheng CB; Basavan D
    Curr Drug Targets; 2022; 23(4):364-372. PubMed ID: 34732115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.